Issue of Equity and Total Voting Rights

Cambridge Cognition Holdings PLC

26 July 2024

 

26 July 2024

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Issue of Equity and Total Voting Rights

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces that further to the announcement on 12 October 2022 regarding the acquisition of eClinicalHealth Limited ("Clinpal"), the Company has today issued 229,984 new ordinary shares of £0.01 each in the share capital of the Company ("New Ordinary Shares") at an issue price of 132.97 pence per New Ordinary Share to certain shareholders of Clinpal, representing approximately £0.3m of the contingent consideration.  No further consideration is due to former shareholders of Clinpal.

Admission and Total Voting Rights

Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that such Admission will take place on or around 8:00 a.m. on or around 31 July 2024.

In accordance with the provision of the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority, the Company confirms that, following the issue of the New Ordinary Shares, its issued ordinary share capital will comprise 41,940,413 Ordinary Shares. There are no shares held in treasury therefore the total number of voting rights in the Company is 41,940,413. This figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in Cambridge Cognition under the FCA's Disclosure and Transparency Rules.

Enquiries:

Cambridge Cognition Holdings plc  Matthew Stork, Chief Executive Officer  Stephen Symonds, Chief Financial Officer  Tel: [phone]  [e-mail]  Panmure Liberum Limited (NOMAD and Joint Broker)  Emma Earl / Freddy Crossley / Mark Rogers   Rupert Dearden  Tel: [phone]  (Corporate Finance)  (Corporate Broking)  Dowgate Capital Limited (Joint Broker)  David Poutney / Nicholas Chambers  Tel: [phone]  Hudson Sandler (Financial PR and IR)  Dan de Belder / Hattie Dreyfus  Tel: [phone]  [e-mail]

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit: https://cambridgecognition.com/

 

END